ABSTRACT
Purpose Our aim was to collect information on delirium assessment processes and pathways in non-intensive care settings in the UK.
Methods We sent a Freedom of Information request to 169 UK NHS hospitals, trusts and health boards (units) in July 2020 to obtain data on usage of delirium assessment tools in clinical practice and delirium pathways or guidelines.
Results We received responses from 154 units (91% response rate). 146 (95%) units reported use of formal delirium assessment processes and 131 (85%) units had guidelines or pathways in place. The 4AT was the most widely used tool, with 117 (80%) units reporting use. The Confusion Assessment Method was used in 652 (45%) units, and the SQiD in 52 (36%) units.
Conclusions Our findings show that the 4AT is the most commonly-used tool in the UK, with 80% of units reporting implementation. This study adds to our knowledge of real-world implementation of delirium detection methods at scale.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not applicable.
Funding Statement
This work was supported by the Wellcome Trust-University of Edinburgh Institutional Strategic Support Fund. Grant no. IS3-T06/03. The financial sponsor played no role in the design, execution, analysis and interpretation of data or writing of the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
As the Freedom of Information Act was used to request data and no person identifiable data were sought, there were no aspects to this study requiring ethics committee approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.